1–42 β-amyloid peptide requires PDK1/nPKC/Rac 1 pathway to induce neuronal death

Translational Psychiatry

Volumn 3, Issue 1, 2013, Pages

  Manterola, L ^a   Hernando Rodriguez M ^b   Ruiz, A ^c,d   Apraiz, A ^c   Arrizabalaga, O ^c   Vellon L ^e   Alberdi, E ^c,d   Cavaliere, F ^c,d   Lacerda, H M ^f   Jimenez, S ^g,h   Parada, L A ⁱ   Matute, C ^c,d   Zugaza, J L ^c,d,j  

^a BIODONOSTIA HEALTH RESEARCH INSTITUTE   (Spain)

^b Centro Nacional de Investigaciones Oncológicas   (Spain)

^c UNIVERSITY OF THE BASQUE COUNTRY UPV EHU   (Spain)

^d ACHUCARRO BASQUE CENTER FOR NEUROSCIENCE   (Spain)

^e Fundacion Inbiomed   (Spain)

^f UNIVERSITY OF TURIN   (Italy)

^g UNIVERSITY OF SEVILLE   (Spain)

^h HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

ⁱ UNIVERSIDAD NACIONAL DE SALTA   (Argentina)

^j BASQUE FOUNDATION FOR SCIENCE   (Spain)

more..

Author keywords

A 1 42; Neuronal death program; Rac 1 GTPase

Indexed keywords

2 AMINO N [4 [5 (2 PHENANTHRENYL) 3 TRIFLUOROMETHYL 1H PYRAZOL 1 YL]PHENYL]ACETAMIDE; 2 MORPHOLINO 8 PHENYLCHROMONE; 2 [1 (3 DIMETHYLAMINOPROPYL) 3 INDOLYL] 3 (3 INDOLYL)MALEIMIDE; AMYLOID BETA PROTEIN[1-42]; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHOINOSITIDE DEPENDENT PROTEIN KINASE 1; PROTEIN KINASE C; RAC1 PROTEIN; 3 PHOSPHOINOSITIDE DEPENDENT PROTEIN KINASE; 3-PHOSPHOINOSITIDE-DEPENDENT PROTEIN KINASE; AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN (1 42); AMYLOID BETA-PROTEIN (1-42); PEPTIDE FRAGMENT; PROTEIN SERINE THREONINE KINASE; RAC1 PROTEIN, RAT;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CELL DEATH; ENZYME INHIBITION; NERVE CELL NECROSIS; NONHUMAN; RAT; SIGNAL TRANSDUCTION; ALZHEIMER DISEASE; ANIMAL; CELL CULTURE; HUMAN; NERVE CELL; NEURITE; PATHOPHYSIOLOGY; PHYSIOLOGY; SPRAGUE DAWLEY RAT;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANIMALS; CELL DEATH; CELLS, CULTURED; HUMANS; NEURITES; NEURONS; PEPTIDE FRAGMENTS; PROTEIN KINASE C; PROTEIN-SERINE-THREONINE KINASES; RAC1 GTP-BINDING PROTEIN; RATS; RATS, SPRAGUE-DAWLEY; SIGNAL TRANSDUCTION;

EID: 84880471379     PISSN: None     EISSN: 21583188     Source Type: Journal    
DOI: 10.1038/tp.2012.147     Document Type: Article

References (78)

1. Parri M, Chiarugi P. Rac and Rho GTPases in cancer cell motility control. Cell Commun Signal 2010; 8: 23.
2. Van Aelst L, D’Souza-Schorey C. Rho GTPases and signaling networks. Genes Dev 1997; 11: 2295–2322.
3. Bustelo XR, Sauzeau V, Berenjeno IM. GTP-binding proteins of the Rho/Rac family: regulation, effectors and functions in vivo. Bioessays 2007; 29: 356–370.
4. Vetter IR, Wittinghofer A. The guanine nucleotide-binding switch in three dimensions. Science 2001; 294: 1299–1304.
5. Wennerberg K, Rossman K, Der C. The Ras superfamily at a glance. J Cell Sci 2005; 1: 843–846.
6. Jaffe AB, Hall A. Rho GTPases: biochemistry and biology. Annu Rev Cell Dev Biol 2005; 21: 247–269.
7. Vega FM, Ridley AJ. Rho GTPases in cancer cell biology. FEBS Lett 2008; 582: 2093–2101.
8. Snapper SB, Rosen FS. The Wiskott–Aldrich syndrome protein (WASP): roles in signaling and cytoskeletal organization. Annu Rev Immunol 1999; 17: 905–929.
9. Boettner B, Van Aelst L. The role of Rho GTPases in disease development. Gene 2002; 286: 155–174.
10. Huesa G, Baltrons MA, Gomez-Ramos P, Moran A, Garcia A, Hidalgo J et al. Altered distribution of RhoA in Alzheimer’s disease and AbetaPP overexpressing mice. J Alzheimers Dis 19: 37–56.
11. Ramakers GJ, Wolfer D, Rosenberger G, Kuchenbecker K, Kreienkamp HJ, Prange-Kiel J et al. Dysregulation of Rho GTPases in the alphaPix/Arhgef6 mouse model of X-linked intellectual disability is paralleled by impaired structural and synaptic plasticity and cognitive deficits. Hum Mol Genet 2012; 21: 268–286.
12. Rudzinski L, Fletcher R, Dickson D, Crook R, Hutton M, Adamson J et al. Early onset alzheimer’s disease with spastic paraparesis, dysarthria and seizures and N135S mutation in PSEN1. Alzheimer Dis Assoc Disord 2009; 22: 299–307.
13. Thomas T, Thomas G, McLendon C, Sutton T, Mullan M. Beta-amyloid-mediated vasoactivity and vascular endothelial damage. Nature 1996; 380: 168–171.
14. Huang Y, Herman M, Liu J, Katsetos C, Wills M, Savory J. Neurofibrillary lesions in experimental aluminum-induced encephalopathy and Alzheimer’s disease share immunoreactivity for amyloid precursor protein, A beta, alpha 1-antichymotrypsin and ubiquitin-protein conjugates. Brain Res 1997; 771: 213–220.
15. Davis-Salinas J, Saporito-Irwin S, Donovan F, Cunningham D, Van Nostrand W. Thrombin receptor activation induces secretion and nonamyloidogenic processing of amyloid beta-protein precursor. J Biol Chem 1994; 269: 22623–22627.
16. Brera B, Serrano A, de Ceballos M. Beta-amyloid peptides are cytotoxic to astrocytes in culture: a role for oxidative stress. Neurobiol Dis 2000; 7: 395–405.
17. Yankner B, Dawes L, Fisher S, Villa-Komaroff L, Oster-Granite M, Neve R. Neurotoxicity of a fragment of the amyloid precursor associated with Alzheimer’s disease. Science 1989; 245: 417–420.
18. Behl C, Davis J, Lesley R, Schubert D. Hydrogen peroxide mediates amyloid beta protein toxicity. Cell 1994; 77: 817–827.
19. Xu J, Chen S, Ahmed S, Chen H, Ku G, Goldberg M et al. Amyloid-beta peptides are cytotoxic to oligodendrocytes. J Neurosci 2001; 21: 1–5.
20. Schapira AH. Oxidative stress and mitochondrial dysfunction in neurodegeneration. Curr Opin Neurol 1996; 9: 260–264.
21. 2 + dysregulation and neuronal death through activation of ionotropic glutamate receptors. Cell Calcium 2010; 47: 264–272.
22. Mao P, Reddy PH. Aging and amyloid beta-induced oxidative DNA damage and mitochondrial dysfunction in Alzheimer’s disease: implications for early intervention and therapeutics. Biochim Biophys Acta 2011; 1812: 1359–1370.
23. Chalimoniuk M, Stolecka A, Cakala M, Hauptmann S, Schulz K, Lipka U et al. Amyloid beta enhances cytosolic phospholipase A2 level and arachidonic acid release via nitric oxide in APP-transfected PC12 cells. Acta Biochim Pol 2007; 54: 611–623.
24. Akiyama H, Barger S, Barnum S, Bradt B, Bauer J, Cole G et al. Inflammation and Alzheimer’s disease. Neurobiol Aging 2000; 21: 383–421.
25. Son JH, Chun HS, Joh TH, Cho S, Conti B, Lee JW. Neuroprotection and neuronal differentiation studies using substantia nigra dopaminergic cells derived from transgenic mouse embryos. J Neurosci 1999; 19: 10–20.
26. Son JH, Kawamata H, Yoo MS, Kim DJ, Lee YK, Kim S et al. Neurotoxicity and behavioral deficits associated with Septin 5 accumulation in dopaminergic neurons. J Neurochem 2005; 94: 1040–1053.
27. Klein W, Krafft G, Finch C. Targeting small Abeta oligomers: the solution to an Alzheimer’s disease conundrum? Trends Neurosci 2001; 24: 219–224.
28. Jimenez S, Torres M, Vizuete M, Sanchez-Varo R, Sanchez Mejias E, Trujillo-Estrada L et al. Age-dependent accumulation of soluble amyloid (A) oligomers reverses the neuroprotective effect of soluble amyloid precursor protein-a(sAPPa) by modulating phosphatidylinositol 3-kinase (PI3k)/Akt-GSK-3 pathway in Alzheimer mouse model. J Biol Chem 2011; 286: 18414–18425.
29. Lowry OH, Rosebrough NJ, Fair AL, Randall RJ. Protein measurement with the Folin phenol reagent. J Biol Chem 1951; 193: 265–275.
30. Arrizabalaga O, Lacerda HM, Zubiaga AM, Zugaza JL. Rac1 protein regulates glycogen phosphorylase activation and controls interleukin (IL)-2-dependent T cell proliferation. J Biol Chem 2012; 287: 11878–11890.
31. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 1983; 65: 55–63.
32. Tada H, Shiho O, Kuroshima K, Koyama M, Tsukamoto K. An improved colorimetric assay for interleukin 2. J Immunol Methods 1986; 93: 157–165.
33. Toullec D, Pianetti P, Coste H, Bellevergue P, Grand-Perret T, Ajakane M et al. The bisindolylmaleimide GF 109203X is a potent and selective inhibitor of protein kinase C. J Biol Chem 1991; 266: 15771–15781.
34. Zugaza JL, Sinnett-Smith J, Van Lint J, Rozengurt E. Protein kinase D (PKD) activation in intact cells through a protein kinase C-dependent signal transduction pathway. EMBO J 1996; 15: 6220–6230.
35. Le Good JA, Ziegler WH, Parekh DB, Alessi DR, Cohen P, Parker PJ. Protein kinase C isotypes controlled by phosphoinositide 3-kinase through the protein kinase PDK1. Science 1998; 281: 2042–2045.
36. Gao T, Toker A, Newton AC. The carboxyl terminus of protein kinase c provides a switch to regulate its interaction with the phosphoinositide-dependent kinase, PDK-1. J Biol Chem 2001; 276: 19588–19596.
37. Martiny-Baron G, Kazanietz MG, Mischak H, Blumberg PM, Kochs G, Hug H et al. Selective inhibition of protein kinase C isozymes by the indolocarbazole Go 6976. J Biol Chem 1993; 268: 9194–9197.
38. Jacobson PB, Kuchera SL, Metz A, Schachtele C, Imre K, Schrier DJ. Anti-inflammatory properties of Go 6850: a selective inhibitor of protein kinase C. J Pharmacol Exp Ther 1995; 275: 995–1002.
39. Coultrap SJ, Sun H, Tenner TE Jr, Machu TK. Competitive antagonism of the mouse 5-hydroxytryptamine3 receptor by bisindolylmaleimide I, a ‘selective’ protein kinase C inhibitor. J Pharmacol Exp Ther 1999; 290: 76–82.
40. Gschwendt M, Müller H, Kielbassa K, Zang R, Kittstein W, Rincke G et al. Rottlerin, a novel protein kinase inhibitor. Biochem Biophys Res Commun 1994; 199: 93–98.
41. Villalba M, Kasibhatla S, Genestier L, Mahboubi A, Green DR, Altman A. Protein kinase ctheta cooperates with calcineurin to induce Fas ligand expression during activation-induced T cell death. J Immunol 1999; 163: 5813–5819.
42. Cordey M, Pike CJ. Conventional protein kinase C isoforms mediate neuroprotection induced by phorbol ester and estrogen. J Neurochem 2006; 96: 204–217.
43. Tiede I, Fritz G, Strand S, Poppe D, Dvorsky R, Strand D et al. CD28-dependent Rac1 activation is the molecular target of azathioprine in primary human CD4 + T lymphocytes. J Clin Invest 2003; 111: 1133–1145.
44. Llorca O, Arias-Palomo E, Zugaza JL, Bustelo XR. Global conformational rearrangements during the activation of the GDP/GTP exchange factor Vav3. EMBO J 2005; 24: 1330–1340.
45. Fleming IN, Elliott CM, Collard JG, Exton JH. Lysophosphatidic acid induces threonine phosphorylation of Tiam1 in Swiss 3T3 fibroblasts via activation of protein kinase C. J Biol Chem 1997; 272: 33105–33110.
46. Goto A, Hoshino M, Matsuda M, Nakamura T. Phosphorylation of STEF/Tiam2 by protein kinase A is critical for Rac1 activation and neurite outgrowth in dibutyryl cAMP-treated PC12D cells. Mol Biol Chem 2011; 22: 1780–1790.
47. Villalba M, Coudronniere N, Deckert M, Teixeiro E, Mas P, Altman A. A novel functional interaction between Vav and PKCtheta is required for TCR-induced T cell activation. Immunity 2000; 12: 151–160.
48. Gao Y, Dickerson JB, Guo F, Zheng J, Zheng Y. Rational design and characterization of a Rac GTPase-specific small molecule inhibitor. Proc Natl Acad Sci USA 2004; 101: 7618–7623.
49. Selkoe DJ. Alzheimer’s disease: a central role for amyloid. J Neuropathol Exp Neurol 1994; 53: 438–447.
50. D -aspartate receptor-dependent mechanism that is blocked by the Alzheimer drug memantine. J Biol Chem 2007; 282: 11590–11601.
51. De Felice FG, Wu D, Lambert MP, Fernandez SJ, Velasco PT, Lacor PN et al. Alzheimer’s disease-type neuronal tau hyperphosphorylation induced by A beta oligomers. Neurobiol Aging 2008; 29: 1334–1347.
52. De Felice FG, Vieira MN, Bomfim TR, Decker H, Velasco PT, Lambert MP et al. Protection of synapses against Alzheimer’s-linked toxins: insulin signaling prevents the pathogenic binding of Abeta oligomers. Proc Natl Acad Sci USA 2009; 106: 1971–1976.
53. Brunet A, Datta SR, Greenberg ME. Transcription-dependent and-independent control of neuronal survival by the PI3K-Akt signaling pathway. Curr Opin Neurobiol 2001; 11: 297–305.
54. Emamian ES, Karayiorgou M, Gogos JA. Decreased phosphorylation of NMDA receptor type 1 at serine 897 in brains of patients with schizophrenia. J Neurosci 2004; 24: 1561–1564.
55. Griffin RJ, Moloney A, Kelliher M, Johnston JA, Ravid R, Dockery P et al. Activation of Akt/ PKB, increased phosphorylation of Akt substrates and loss and altered distribution of Akt and PTEN are features of Alzheimer’s disease pathology. J Neurochem 2005; 93: 105–117.
56. Norton N, Williams HJ, Dwyer S, Carroll L, Peirce T, Moskvina V et al. Association analysis of AKT1 and schizophrenia in a UK case control sample. Schizophr Res 2007; 93: 58–65.
57. Magrane J, Rosen KM, Smith RC, Walsh K, Gouras GK, Querfurth HW. Intraneuronal beta-amyloid expression downregulates the Akt survival pathway and blunts the stress response. J Neurosci 2005; 25: 10960–10969.
58. Lee HK, Kumar P, Fu Q, Rosen KM, Querfurth HW. The insulin/Akt signaling pathway is targeted by intracellular beta-amyloid. Mol Biol Cell 2009; 20: 1533–1544.
59. Vanhaesebroeck B, Alessi DR. The PI3K-PDK1 connection: more than just a road to PKB. Biochem J 2000; 346(Part 3): 561–576.
60. Weinreb O, Bar-Am O, Amit T, Chillag-Talmor O, Youdim MB. Neuroprotection via pro-survival protein kinase C isoforms associated with Bcl-2 family members. FASEB J 2004; 18: 1471–1473.
61. Maher P. How protein kinase C activation protects nerve cells from oxidative stress-induced cell death. J Neurosci 2001; 21: 2929–2938.
62. Choi BH, Hur EM, Lee JH, Jun DJ, Kim KT. Protein kinase Cdelta-mediated proteasomal degradation of MAP kinase phosphatase-1 contributes to glutamate-induced neuronal cell death. J Cell Sci 2006; 119(Part 7): 1329–1340.
63. Konishi H, Tanaka M, Takemura Y, Matsuzaki H, Ono Y, Kikkawa U et al. Activation of protein kinase C by tyrosine phosphorylation in response to H2O2. Proc Natl Acad Sci USA 1997; 94: 11233–11237.
64. Denning MF, Wang Y, Nickoloff BJ, Wrone-Smith T. Protein kinase Cdelta is activated by caspase-dependent proteolysis during ultraviolet radiation-induced apoptosis of human keratinocytes. J Biol Chem 1998; 273: 29995–30002.
65. Majumder PK, Pandey P, Sun X, Cheng K, Datta R, Saxena S et al. Mitochondrial translocation of protein kinase C delta in phorbol ester-induced cytochrome c release and apoptosis. J Biol Chem 2000; 275: 21793–21796.
66. Reyland ME, Barzen KA, Anderson SM, Quissell DO, Matassa AA. Activation of PKC is sufficient to induce an apoptotic program in salivary gland acinar cells. Cell Death Differ 2000; 7: 1200–1209.
67. Matassa AA, Carpenter L, Biden TJ, Humphries MJ, Reyland ME. PKCdelta is required for mitochondrial-dependent apoptosis in salivary epithelial cells. J Biol Chem 2001; 276: 29719–29728.
68. Kim YH, Choi MY, Kim YS, Han JM, Lee JH, Park CH et al. Protein kinase C delta regulates anti-apoptotic alphaB-crystallin in the retina of type 2 diabetes. Neurobiol Dis 2007; 28: 293–303.
69. Kim YH, Kim YS, Park CH, Chung IY, Yoo JM, Kim JG et al. Protein kinase C-delta mediates neuronal apoptosis in the retinas of diabetic rats via the Akt signaling pathway. Diabetes 2008; 57: 2181–2190.
70. Smith MA, Richey Harris PL, Sayre LM, Beckman JS, Perry G. Widespread peroxynitrite-mediated damage in Alzheimer’s disease. J Neurosci 1997; 17: 2653–2657.
71. Matsuoka Y, Picciano M, La Francois J, Duff K. Fibrillar beta-amyloid evokes oxidative damage in a transgenic mouse model of Alzheimer’s disease. Neuroscience 2001; 104: 609–613.
72. Babior BM. NADPH oxidase: an update. Blood 1999; 93: 1464–1476.
73. Lambeth JD. NOX enzymes and the biology of reactive oxygen. Nat Rev Immunol 2004; 4: 181–189.
74. McDonald DR, Brunden KR, Landreth GE. Amyloid fibrils activate tyrosine kinase-dependent signaling and superoxide production in microglia. J Neurosci 1997; 17: 2284–2294.
75. Combs CK, Johnson DE, Cannady SB, Lehman TM, Landreth GE. Identification of microglial signal transduction pathways mediating a neurotoxic response to amyloidogenic fragments of beta-amyloid and prion proteins. J Neurosci 1999; 19: 928–939.
76. Bianca VD, Dusi S, Bianchini E, Dal Pra I, Rossi F. Beta-amyloid activates the O-2 forming NADPH oxidase in microglia, monocytes, and neutrophils. A possible inflammatory mechanism of neuronal damage in Alzheimer’s disease. J Biol Chem 1999; 274: 15493–15499.
77. Ma QL, Yang F, Calon F, Ubeda OJ, Hansen JE, Weisbart RH et al. P21-activated kinase-aberrant activation and translocation in Alzheimer disease pathogenesis. J Biol Chem 2008; 283: 14132–14143.
78. Knobloch M, Mansuy IM. Dendritic spine loss and synaptic alterations in Alzheimer’s disease. Mol Neurobiol 2008; 37: 73–82.